Hidenao Kayawake

Hidenao Kayawake

Auto-generated profile, based on publicly available information

Hidenao Kayawake

Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
HKHidenao Kayawake
Hidenao Kayawake
NONorihito Okumura
Norihito Okumura
KYKeiji Yamanashi
Keiji Yamanashi
ATAyuko Takahashi
Ayuko Takahashi
SISatoshi Itasaka
Satoshi Itasaka
TMTomoaki Matsuoka
Tomoaki Matsuoka

22 December 2020 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
HKHidenao Kayawake
Hidenao Kayawake
TCToyofumi F Chen-Yoshikawa
Toyofumi F Chen-Yoshikawa
FGFumiaki Gochi
Fumiaki Gochi
STSatona Tanaka
Satona Tanaka
KYKimiko Yurugi
Kimiko Yurugi
HDHiroshi Date
Hiroshi Date
OBJECTIVES: Few studies have evaluated the outcomes of lung transplantation (LTx) in recipients with preformed donor-specific antibodies (DSAs). This study investigated the postoperative changes in preformed DSAs based on prospectively collected data of DSAs, and the influences of preformed DSAs on postoperative outcomes among LTx recipients. METHODS: Between July 2010 and December 2019, 216 recipients underwent LTx (81 living-donor lobar lung transplants and 135 deceased-donor lung transplants). We reviewed 8 cases with preformed DSAs to determine postoperative changes in DSAs and compared postoperative outcomes between recipients with and without DSAs. RESULTS: The preoperative mean fluorescence intensity of preformed DSAs ranged from 1141 to 14 695. Two recipients experienced antibody-mediated rejection within 2 weeks after LTx. DSAs disappeared in 7 recipients; however, 1 recipient experienced the relapse of DSAs and died from chronic lung allograft syndrome (CLAD), whereas 1 recipient had persisting DSAs within the study period and died from CLAD. Neither overall survival (OS) nor CLAD-free survival was significantly different between recipients with and without DSAs (P = 0.26 and P = 0.17, respectively). However, both OS and CLAD-free survival were significantly lower in recipients with DSAs against HLA class II than in those without these antibodies {5-year OS: 25.0% [95% confidence interval (CI): 0.9–66.5%] vs 72.1% (95% CI: 63.8–78.9%), P = 0.030 and 5-year CLAD-free survival: 26.7% (95% CI: 1.0–68.6%) vs 73.7% (95% CI: 66.5–79.5%), P = 0.002}. CONCLUSIONS: Prognosis in recipients experiencing the relapse of preformed DSAs and those with persisting DSAs may be poor. The recipients with anti-HLA class II preformed DSAs had a significantly worse prognosis.

15 December 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
STSatona Tanaka
Satona Tanaka
DNDaisuke Nakajima
Daisuke Nakajima
RSRyo Sakamoto
Ryo Sakamoto
TOTsuyoshi Oguma
Tsuyoshi Oguma
AKAtsushi Kawaguchi
Atsushi Kawaguchi
HDHiroshi Date
Hiroshi Date

26 February 2019 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
HKHidenao Kayawake
Hidenao Kayawake
TCToyofumi F. Chen-Yoshikawa
Toyofumi F. Chen-Yoshikawa
HDHiroshi Date
Hiroshi Date
Selecting the proper surgical approach for mediastinal tumors in the thoracic outlet is difficult. Video-assisted thoracoscopic surgery is ideal because of the less invasiveness; however, it is often difficult to resect tumors only by video-assisted thoracoscopic surgery due to the poor visualization of the cranial side of tumors. We report two successfully treated cases by using a dual approach consisting of the transmanubrial osteomuscular sparing technique and video-assisted thoracoscopic surgery for aiming both the less invasiveness and the good visualization of the cranial side of tumors. We present two resected cases of the mediastinal tumor in the thoracic outlet. The first case was a 28-year-old woman and the second case was a 37-year-old man. They had a mediastinal tumor in the thoracic outlet which was detected on the roentgenogram. A definitive preoperative diagnosis was unavailable. The surgical resection was started with video-assisted thoracoscopic surgery in the both cases. After the dissection of the caudal side of the tumor, the dissection of the cranial side was judged to be difficult and risky because the tumor was located adjacent to major vessels and the good visualization of this side couldn’t be acquired. Therefore, the transmanubrial approach was sequentially performed and complete resection was safely achieved. Postoperatively, although transient Horner syndrome appeared in both cases, they recovered from this syndrome and were discharged. The final diagnosis was schwannoma for both cases. Neither of the cases had any functional restriction of the upper extremity. This dual approach for mediastinal tumors in the thoracic outlet is useful in terms of safety and lower invasiveness.

6 August 2018 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
HKHidenao Kayawake
Hidenao Kayawake
NONorihito Okumura
Norihito Okumura
KYKeiji Yamanashi
Keiji Yamanashi
YOYasuhiro Otsuki
Yasuhiro Otsuki
ATAyuko Takahashi
Ayuko Takahashi
TMTomoaki Matsuoka
Tomoaki Matsuoka

4 May 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
DNDaisuke Nakajima
Daisuke Nakajima
IYItsuki Yuasa
Itsuki Yuasa
HKHidenao Kayawake
Hidenao Kayawake
STSatona Tanaka
Satona Tanaka
YYYoshito Yamada
Yoshito Yamada
HDHiroshi Date
Hiroshi Date
ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graft-versus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT.